Cite
APA Citation
Wen, F., Zheng, H., Zhang, P., Hutton, D., & Li, Q. (2018). oPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ open, 8(4), . http://access.bl.uk/ark:/81055/vdc_100135542803.0x000007